Phase I trial of zoledronic acid + imatinib mesylate (Gleevec) in patients with bone metastases

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 33, Issue 1, 2010, Pages 75-78

  Lipton, Allan ^a   Campbell Baird, Cynthia ^a   Harvey, Harold ^a   Kim, Christian ^a   Demers, Laurence ^a   Costa, Luis ^b  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b HOSPITAL DE SANTA MARIA   (Portugal)

Author keywords

Bone metastases; Gleevec; Platelet derived growth factor; Zoledronic acid

Indexed keywords

CALCIUM; DIURETIC AGENT; IMATINIB; VITAMIN D; ZOLEDRONIC ACID;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BELL PALSY; BONE METASTASIS; BONE PAIN; BRAIN ISCHEMIA; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVITIS; DEPRESSION; DRUG TOLERABILITY; DRY SKIN; FATIGUE; GASTROESOPHAGEAL REFLUX; HEART INFARCTION; HEMATURIA; HUMAN; HYPERCALCEMIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; INFECTION; LEG EDEMA; MUSCLE CRAMP; NAUSEA AND VOMITING; NEUTROPENIA; PAIN; PERIORBITAL EDEMA; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PROTEINURIA; QUALITY OF LIFE; RASH; SIDE EFFECT; STEREOTACTIC RADIOSURGERY; TASTE DISORDER; THROMBOCYTOPENIA; VISION; VITAMIN SUPPLEMENTATION;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; BREAST NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; KIDNEY NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; NEOPLASM STAGING; PIPERAZINES; PROGNOSIS; PROSTATIC NEOPLASMS; PYRIMIDINES; SARCOMA; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 76749165277     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31819cccdc     Document Type: Article

References (13)

1. Plunkett TA, Smith P, Rubens RD. Risk of complications from bone metastases in breast cancer: implications for management. Eur J Cancer. 2000;36: 476-484.
2. Dirks RP, Bloemers HP. Signals controlling the expression of PDGF-review-. Mol Biol Rep. 1995-1996;22:1-24.
3. Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev. 1999;79:1283-1316.
4. Lev DC, Kim SJ, Onn A, et al. Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice. Clin Cancer Res. 2005;11:306-314.
5. Uehara H, Kim SJ, Karashima T, et al. Effects of blocking platelet-derived growth factor receptor signaling in a mouse model of experimental prostate cancer bone metastases. J Natl Cancer Inst. 2003;95:458-470.
6. Canalis E, Varghese S, McCarthy TL, et al. Role of platelet-derived growth factor in bone cell function. Growth Regul. 1992;2:151-155.
7. Roodman GD. Role of stromal-derived cytokines and growth factors in bone metastasis. Cancer. 2003;97:733-738.
8. Zhang Z, Chen J, Jin D. Platelet-derived growth factor (PDGF)-BB stimulates osteoclastic bone resorption directly: the role of receptor B. Biochem Biophys Res Commun. 1998;251:190-194.
9. Franchimont N, Canalis E. Platelet-derived growth factor stimulates the synthesis of interleukin-6 in cells of the osteoblast lineage. Endocrinology. 1995;136:5469-5475.
10. Kubota K, Sakikawa C, Katsumata M, et al. Platelet-derived growth factor- BB secreted from osteoclasts acts as an osteoblastogenesis inhibitory factor. J Bone Miner Res. 2002;17:257-265.
11. Yi B, Williams PJ, Niewolna M, et al. Tumor-derived platelet-derived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer. Cancer Res. 2002;62:917-923.
12. Mathew P, Fidler IJ, Logothetis CJ. Combination docetaxel and plateletderived growth factor receptor inhibition with imatinib mesylate in prostate cancer. Semin Oncol. 2004;31(suppl 6):24-29. (Pubitemid 38879419)
13. Paget S. The distribution of secondary growths in cancer of the breast. Lancet. 1889;1:571-573.